Germany Exhibition Health (000813): Intends To Increase Capital To Beijing Oriental

　　德展健康(000813.SZ)公布，公司为进一步加快在大健康领域的技术研发和应用，通过投资驱动加速大健康产业链的布局，公司与北京东方略生物医药科技股份有限公司(“北京东方略”、“标的公司”)及其原股东(上海仟德股权投资合伙企业(有限合伙)、仇思念、世耀生物医药技术(上海)有限公司、嘉兴星空倍益投资合伙企业(有限合伙)、陈明键、深圳市熔岩奕新投资合伙企业(有限合伙)、杨维平、达孜东方高圣夏雨资本管理有限公司、上海展高股权投资合伙企业(有限合伙)、张驰、融智开普创业投资(北京)有限公司)经友好协商于2019年12月16日在北京市朝阳区共同签署了《北京东方略生物医药科技股份有限公司增资协议》(“增资协议”)，公司拟对北京东方略进行增资，公司根据增资协议的条款和条件以其合法拥有的现金出资3亿元认购标的公司此次新增3615万股股份，超 The amount of newly registered capital is 263 million 850 thousand yuan, which is included in the capital reserve of the target company. Beijing Eastern slightly unanimously agreed that the registered capital of Beijing orient slightly increased from 119 million 530 thousand yuan to 155 million 680 thousand yuan.

Beijing Oriental bio pharmaceutical Polytron Technologies Inc business scope: Sales of medical devices category III; retail drugs; medical research and testing development; natural science research and test development: technology development, technology transfer, technology consulting, technical services; technology import and export, import and export of goods, agents import and export; sales of medical devices category I and II. (enterprises choose their own business projects according to law and carry out their business activities: the projects that are approved according to law must be approved by the relevant departments and carry out business activities in accordance with the approved contents; they shall not be allowed to engage in any business activities prohibited or restricted by industrial policies in this Municipality. )

Orient is a biopharmaceutical company focusing on the clinical development and commercialization of cancer innovative drugs. Its important variety is the exclusive licensing of patents and know-how in the Greater China region (mainland China, Taiwan, Hongkong and Macao) for the DNA therapeutic vaccine targeting HPV cervical cancer precancerous lesions. In addition, there are a number of products in pre clinical / clinical stages. VGX-3100 is mainly used for the treatment of cervical cancer precancerous lesions caused by HPV16 and HPV18 virus infection. It is necessary to change the status quo of cervical cancer precancerous lesions, mainly rely on cervical conization and hysterectomy, and reduce the risk of recurrence. At the same time, the elimination of HPV virus and the prevention of cervical cancer can further reduce the incidence of cervical cancer. The product has huge potential market in China. This transaction can help Germany to enrich its own product line and expand its market. For the company's continuous layout in the field of cancer, improve the company's industry influence and comprehensive competitiveness, in line with the company's long-term development strategy.

The transaction price is determined by reference value and negotiated price is fair, and there is no damage to the interests of the company and shareholders. The foreign investment project is expected to have no substantial impact on the health performance of Germany exhibition in the near future, and will become a new profit growth point in the future.